CN105641016A - Pharmaceutical composition for treating coronary heart disease - Google Patents
Pharmaceutical composition for treating coronary heart disease Download PDFInfo
- Publication number
- CN105641016A CN105641016A CN201610047305.7A CN201610047305A CN105641016A CN 105641016 A CN105641016 A CN 105641016A CN 201610047305 A CN201610047305 A CN 201610047305A CN 105641016 A CN105641016 A CN 105641016A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- weight portion
- ethanol
- percent concentration
- heart disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Abstract
The invention discloses a pharmaceutical composition for treating a coronary heart disease and a preparation method thereof. The pharmaceutical composition is prepared by taking torularia humilis, herb of sanicula astrantifolia Wolff ex Kresch., asarinin and xylopinine as bulk pharmaceuticals in proportion and can be prepared into various dosage forms according to a conventional preparation technology, and the coronary heart disease treating effect is significant.
Description
Technical field
The invention belongs to technical field of Chinese medicines, particularly relate to a kind of pharmaceutical composition treating coronary heart disease and preparation method thereof.
Background technology
Recently as the transformation of the raising of people's living standard and life style, the sickness rate of cardiovascular disease is more and more higher, wherein most commonly seen with angina pectoris. One group of clinical syndrome that angina pectoris causes coronary stenosis to occur after causing myocardial ischemia-anoxemia after referring to coronary atherosclerosis be cardinal symptom with precordialgia. Bringing painful greatly and stress during angina pectoris attacks to patient, and unstable angina pectoris has the possibility developing into acute myocardial infarction, the life and health of people in serious threat. The main policies of current clinical treatment coronary heart disease is that drug administration prevents and controls symptom.
Rhythm of life is fast, life stress is big, is often among muscle power and the mental work of high intensity so that the sickness rate of coronary heart disease remains high. The risk factor of cardiovascular disease is generically and collectively referred to as metabolism syndrome, it mainly includes central obesity, type 2 diabetes mellitus or IGR, hyperlipemia and hypertension, in addition with advanced age, smoking, drink, hyperhomocysteinemiainjury, hyperuricemia, Endocrine disorders and polycystic ovarian syndrome. Patients with coronary heart disease is often accompanied by coronarius atherosis and narrow so that heart can not regulate self blood flow according to myocardial oxygen consumption, causes myocardial ischemia-anoxemia angina pectoris symptom occur. The traditional Chinese medical science is thought, angina pectoris belongs to the category of " pained " " thoracic obstruction ", and its pathogenesis is that insufficiency of heart-QI is weary, fortune blood is unable, and slow blood flow causes that QI and blood is not smooth, stagnation of QI and blood may bring about pain. Thus its rule for the treatment of is in that supplementing QI and nourishing YIN, activating collaterals and eliminating stagnation, blood stasis dispelling reduce phlegm, treating both the principal and secondary aspects of a disease.
Earthworm fruit mustard: this product is the dry herb of crucifer earthworm fruit mustard Torulariahumilis (C.A.Meyer) O.E.Schulz.. Main product in Qinghai, Tibet, Gansu, the ground such as Shaanxi. Gather herb the 8-9 month, remove impurity, dry. [nature and flavor] acrid in the mouth, warm in nature. [function with cure mainly] helps digestion, and solves meat poison. For dyspepsia, meat poison. [character] this product is irregular section. Herb is by branched fine hair. Root is thin, section milky, opaque. Stem grass green, cylindrical, section is smooth, skin zone's canescence, center tool marrow. Leaf-shrinkage, bar spoon shape, tip circle is blunt. Inflorescence umbrella room shape, sepal Long Circle, have narrow film quality limit, corolla white, oblong, base portion pinch becomes pawl, angle fruit curved elongated, slightly becomes beads shape, top tool beak. Seed is oval, is about 1mm, surface tool longitudinal grin. Feeble QI, taste is micro-puckery. Record in Qinghai Province's Tibetan medicine concocted specification (version in 2010).
Herba Saniculae Astrantifoliae: this product is the herb of Yunnan, samphire river sanicle SaniculaastrantifoliaWolffexKresch..The 6-9 month gathers, and dries. [nature and flavor] hardship pungent, micro-, temperature. [return through] returns Liver Channel. [function cures mainly] wind-damp dispelling; The meridian dredging. Main air pain of dampness syndrome; Muscle arteries and veins contracture; Traumatic injury. [former phytomorph] perennial herb, high 30-70cm. Herb is without hair. Root tubbiness, has most elongated supporting root. Stem is upright, and top is stood, top 2-4 dichotomy. The long 5-20cm of basal leaf petiole, base portion has wide film quality sheath. The nearly keratin of blade, heart shaped triangle forms round kidney shape, long 2.5-8cm, wide 2.5-9cm, and palmate three is molten to be split, middle sliver width obovate, and side sliver whip shape ovum shape lanceolar has again 1-2 deeply to incise sometimes, and there is thick crenature at edge, and increment has mucro, palmate vein 3-5. Universal umbel top is raw; Phyllary is several, linear; Umbrella spoke minority; Involucel sheet 7-10, linear; Umbellule has about 10, flower; Calyx tooth trace shape lanceolar; Petal obovate is white or pink; Style outwards launches. Diachenium inverted cone-shaped, is about 2mm, below prickle short, top prickle is hook-shaped, golden yellow or aubergine; Mitogenetic fruit cross section is rounded, and the endosperm outside of belly is straight, and oil pipe is little, inconspicuous. Flower, fruit month phase 7-10. Record in Chinese medicine voluminous dictionary.
Asarinin (Asarinin): CAS 133-05-1, molecular formula C20H18O6, molecular weight 354.35. Pyrethrum is have sensitization by [pharmacological action]. [ingredient origin] Arnold jacquard weave green pepper Zanthaxylumarnottianum, get Ka Rui Pericarpium Zanthoxyli Zanthoxylumdecatyi, Fructus Piperis Pericarpium Zanthoxyli Zanthoxylumpiperitum, royal paulownia Paulowniatomentosa, Herba Asari A.sarum.sieboldii.
Xylopinine (Xylopinine): CAS 6872-27-1, molecular formula C21H25NO4, molecular weight 355.43. [pharmacological action] antitussive, eliminates the phlegm, relievings asthma, calm, epinephrine a-receptor blocking agent. [ingredient origin] Sirikaya separates wood lobe tree bark, menispermaceous plants greenyellow stephania root bark with plant.
2 crude drug chemical constitutions:
Asarinin (Asarinin) xylopinine (Xylopinine).
Summary of the invention
It is an object of the invention to overcome the deficiency of background technology, it is provided that pharmaceutical composition of a kind of effective treatment coronary heart disease and preparation method thereof.
The present invention adopts the following technical scheme that realization:
Composition and the weight portion of making the crude drug of the pharmaceutical composition of this treatment coronary heart disease be:
Earthworm fruit mustard 1800-1860 weight portion Herba Saniculae Astrantifoliae 1600-1680 weight portion asarinin 80-90 weight portion xylopinine 90-92 weight portion.
It is preferably used in the pharmaceutical composition for the treatment of coronary heart disease, is prepared by the crude drug composition of weight portion:
Earthworm fruit mustard 1830 weight portion Herba Saniculae Astrantifoliae 1640 weight portion asarinin 85 weight portion xylopinine 91 weight portion.
A kind of pharmaceutical composition treating coronary heart disease, it is characterised in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to prepare into tablet or capsule or drop pill.
A kind of pharmaceutical composition treating coronary heart disease, it is characterised in that the treatment medicaments for coronary disease that pharmaceutical composition forms with chemical drugs or Chinese medicine.
The preparation method of a kind of pharmaceutical composition treating coronary heart disease, it is characterised in that prepare as follows:
The composition of crude drug and weight portion be: earthworm fruit mustard 1800-1860 weight portion Herba Saniculae Astrantifoliae 1600-1680 weight portion asarinin 80-90 weight portion xylopinine 90-92 weight portion;
Preparation method:
(1) earthworm fruit mustard is taken by crude drug proportioning, Herba Saniculae Astrantifoliae, asarinin, xylopinine, mixing, with weight percent concentration 33% ethanol as solvent, extract at 45 DEG C of warm macerating, extraction time is 14 times, each extraction time is 3.0 hours, each solvent load is 28 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, it is concentrated into relative density 1.12, filter, medicinal liquid passes through D784 macroporous adsorptive resins, first wash with water, again with weight percent concentration 80% alcoholic solution eluting D784 macroporous adsorptive resins, collect weight percent concentration 80% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is taken, with weight percent concentration 70% ethanol as solvent, heating and refluxing extraction 2 times, each extraction time is 1.5 hours, each solvent load is 18 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, it is concentrated into relative density 1.15, filter, medicinal liquid passes through D185 macroporous adsorptive resins, first wash with water, again with weight percent concentration 90% alcoholic solution eluting D185 macroporous adsorptive resins, collect weight percent concentration 90% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) extract A and extract B are mixed, obtain pharmaceutical composition.
The preferably preparation method of a kind of pharmaceutical composition treating coronary heart disease, it is characterised in that prepare as follows:
The composition of crude drug and weight portion be: earthworm fruit mustard 1830 weight portion Herba Saniculae Astrantifoliae 1640 weight portion asarinin 85 weight portion xylopinine 91 weight portion;
Preparation method:
(1) earthworm fruit mustard is taken by crude drug proportioning, Herba Saniculae Astrantifoliae, asarinin, xylopinine, mixing, with weight percent concentration 33% ethanol as solvent, extract at 45 DEG C of warm macerating, extraction time is 14 times, each extraction time is 3.0 hours, each solvent load is 28 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, it is concentrated into relative density 1.12, filter, medicinal liquid passes through D784 macroporous adsorptive resins, first wash with water, again with weight percent concentration 80% alcoholic solution eluting D784 macroporous adsorptive resins, collect weight percent concentration 80% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is taken, with weight percent concentration 70% ethanol as solvent, heating and refluxing extraction 2 times, each extraction time is 1.5 hours, each solvent load is 18 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, it is concentrated into relative density 1.15, filter, medicinal liquid passes through D185 macroporous adsorptive resins, first wash with water, again with weight percent concentration 90% alcoholic solution eluting D185 macroporous adsorptive resins, collect weight percent concentration 90% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) extract A and extract B are mixed, obtain pharmaceutical composition.
The preparation method of a kind of pharmaceutical composition treating coronary heart disease, it is characterised in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to prepare into tablet or capsule or drop pill.
The preparation method of a kind of pharmaceutical composition treating coronary heart disease, it is characterised in that pharmaceutical composition and chemical drugs or Chinese medicine composition treatment medicaments for coronary disease.
Medicine composite for curing children's's deficiency of YIN intestinal dryness type constipation cure rate and total effective rate, higher than matched group, are the active drugs for the treatment of children's's deficiency of YIN intestinal dryness type constipation.
Detailed description of the invention
Embodiment 1: pharmaceutical composition for the treatment of coronary heart disease and preparation method thereof
The composition of crude drug and the weight portion of the pharmaceutical composition for the treatment of coronary heart disease be: earthworm fruit mustard 1830g Herba Saniculae Astrantifoliae 1640g asarinin 85g xylopinine 91g;
Preparation method:
(1) earthworm fruit mustard is taken by crude drug proportioning, Herba Saniculae Astrantifoliae, asarinin, xylopinine, mixing, with weight percent concentration 33% ethanol as solvent, extract at 45 DEG C of warm macerating, extraction time is 14 times, each extraction time is 3.0 hours, each solvent load is 28 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, it is concentrated into relative density 1.12, filter, medicinal liquid passes through D784 macroporous adsorptive resins, first wash with water, again with weight percent concentration 80% alcoholic solution eluting D784 macroporous adsorptive resins, collect weight percent concentration 80% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is taken, with weight percent concentration 70% ethanol as solvent, heating and refluxing extraction 2 times, each extraction time is 1.5 hours, each solvent load is 18 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, it is concentrated into relative density 1.15, filter, medicinal liquid passes through D185 macroporous adsorptive resins, first wash with water, again with weight percent concentration 90% alcoholic solution eluting D185 macroporous adsorptive resins, collect weight percent concentration 90% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) extract A and extract B are mixed, obtain pharmaceutical composition.
Embodiment 2: pharmaceutical composition for the treatment of coronary heart disease and preparation method thereof
The composition of crude drug and the weight portion of the pharmaceutical composition for the treatment of coronary heart disease be: earthworm fruit mustard 1800g Herba Saniculae Astrantifoliae 1680g asarinin 80g xylopinine 92g;
Preparation method:
(1) earthworm fruit mustard is taken by crude drug proportioning, Herba Saniculae Astrantifoliae, asarinin, xylopinine, mixing, with weight percent concentration 33% ethanol as solvent, extract at 45 DEG C of warm macerating, extraction time is 14 times, each extraction time is 3.0 hours, each solvent load is 28 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, it is concentrated into relative density 1.12, filter, medicinal liquid passes through D784 macroporous adsorptive resins, first wash with water, again with weight percent concentration 80% alcoholic solution eluting D784 macroporous adsorptive resins, collect weight percent concentration 80% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is taken, with weight percent concentration 70% ethanol as solvent, heating and refluxing extraction 2 times, each extraction time is 1.5 hours, each solvent load is 18 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, it is concentrated into relative density 1.15, filter, medicinal liquid passes through D185 macroporous adsorptive resins, first wash with water, again with weight percent concentration 90% alcoholic solution eluting D185 macroporous adsorptive resins, collect weight percent concentration 90% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) extract A and extract B are mixed, obtain pharmaceutical composition.
Embodiment 3: pharmaceutical composition for the treatment of coronary heart disease and preparation method thereof
The composition of crude drug and the weight portion of the pharmaceutical composition for the treatment of coronary heart disease be: earthworm fruit mustard 1860g Herba Saniculae Astrantifoliae 1600g asarinin 90g xylopinine 90g;
Preparation method:
(1) earthworm fruit mustard is taken by crude drug proportioning, Herba Saniculae Astrantifoliae, asarinin, xylopinine, mixing, with weight percent concentration 33% ethanol as solvent, extract at 45 DEG C of warm macerating, extraction time is 14 times, each extraction time is 3.0 hours, each solvent load is 28 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, it is concentrated into relative density 1.12, filter, medicinal liquid passes through D784 macroporous adsorptive resins, first wash with water, again with weight percent concentration 80% alcoholic solution eluting D784 macroporous adsorptive resins, collect weight percent concentration 80% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is taken, with weight percent concentration 70% ethanol as solvent, heating and refluxing extraction 2 times, each extraction time is 1.5 hours, each solvent load is 18 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, it is concentrated into relative density 1.15, filter, medicinal liquid passes through D185 macroporous adsorptive resins, first wash with water, again with weight percent concentration 90% alcoholic solution eluting D185 macroporous adsorptive resins, collect weight percent concentration 90% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) extract A and extract B are mixed, obtain pharmaceutical composition.
Embodiment 4: the preparation of tablet
Example 1 pharmaceutical composition 207g, adds starch 173g, mixing, granulates, dry, adds microcrystalline Cellulose 16g, magnesium stearate 4g, and mixing is pressed into 1000, obtains medicinal composition tablets.
Embodiment 5: the preparation of capsule
Example 2 pharmaceutical composition 207g, adds starch 193g, mixing, granulates, dry, and granulate adds appropriate magnesium stearate, mixing, encapsulated 1000, obtains medicament composition capsule.
Embodiment 6: the preparation of drop pill
Weigh polyethylene glycol 6000 203g water-bath (80 DEG C) heating and boil molten, add embodiment 3 pharmaceutical composition 16g, stir, with liquid paraffin for coolant, put in glass tubing (4*80cm), chilling temperature is 8 DEG C, drip internal-and external diameter is 7.0/1.5 (mm/mm), and drip is 1.5cm from liquid level, drips speed with per minute 51 for optimum condition, blot the condensing agent on drop pill surface with cotton, obtain medicament composition dropping pills.
Embodiment 7: the pharmaceutical composition for the treatment of coronary heart disease
The composition of crude drug and the weight portion of the pharmaceutical composition for the treatment of coronary heart disease be:
Earthworm fruit mustard 1713 weight portion asarinin 93 weight portion xylopinine 63 weight portion.
Embodiment 8: the pharmaceutical composition for the treatment of coronary heart disease
The composition of crude drug and the weight portion of the pharmaceutical composition for the treatment of coronary heart disease be:
Herba Saniculae Astrantifoliae 1710 weight portion asarinin 94 weight portion xylopinine 76 weight portion.
Embodiment 9: the pharmaceutical composition for the treatment of coronary heart disease
The composition of crude drug and the weight portion of the pharmaceutical composition for the treatment of coronary heart disease be:
Earthworm fruit mustard 1506 weight portion asarinin 65 weight portion xylopinine 75 weight portion Herba Saniculae Astrantifoliae 1202 weight portion.
Experimental example 1: treatment coronary heart disease Experiment on Function research
1. physical data
Choosing in March, 2010��2011 year March is object of study at 28 example patients with coronary heart disease of this city hospital for treatment, and all patients all meet the angina pectoris diagnostic criteria that ACC expert formulates; There is anginal classical symptom and sign, with ECG change during outbreak.
Exclusion standard: the person that 1. very likely develops into acute myocardial infarction; 2. merge serious hepatorenal disease, hematologic disease and have bleeding tendency person; 3. compliance is poor, and treatment is less than person's course for the treatment of; 4. to trial drug allergy sufferers. All patients are divided into according to random, voluntary principle matched group and treatment group, often organize each 14 examples. Two groups of patients without significant difference, have comparability in sex, age, the course of disease and the state of an illness.
2. Therapeutic Method
All patients all give coronary heart disease conventional therapy, including less salt low fat diet, antiplatelet aggregation (visiing aspirin), fat-reducing medicament (statins), stabilizing blood pressure (amlodipine or ACEClass medicine).
Matched group patient adds with isosorbide dinitrate tablets (trade name: sorbitrate, Baijingyu Pharmaceutical Co., Ltd., Nanjing, the quasi-word H32024005 of traditional Chinese medicines) oral on basis of conventional therapy.
Treatment group patient adds pharmaceutical composition oral (embodiment 1 pharmaceutical composition lot number 20100117) on basis of conventional therapy.
The course for the treatment of is 1 month. After comparison therapy during the clinical effectiveness of two groups of patients and medication untoward reaction a situation arises.
3. therapeutic outcome
Criterion of therapeutical effect: evaluate clinical effectiveness according to method conventional in document, ECG Change when clinical symptoms and outbreak when Main Basis is angina pectoris attacks number of times, outbreak.Effective: angina pectoris does not show effect or attack times reduces more than 80% earlier above, without obvious chest pain during outbreak; Effective: attack times reduces 50%��80% earlier above, and during outbreak, chest pain substantially alleviates earlier above; Invalid: attack times and chest pain degree are earlier above without significant change, and during outbreak, chest pain continues without alleviating, and even progress is acute myocardial infarction or sudden cardiac death. ECG curative effect is evaluated. Effective: under quiescent condition, electrocardiogram is normal; Effective: during outbreak, electrocardiogram prompting ST section is forced down minimizing more than 0.1mV, T ripple and is inverted to shoal earlier above and reaches more than 50% or transfer to upright; Invalid: during outbreak, electrocardiogram is not improved and even occurs that myocardial infarction changes. Total effective rate=(effective+effectively)/total number of cases �� 100%.
3.1 liang of group patient clinical effectiveness comparison
Result is in Table 1.
Table 1 matched group and treatment group patient clinical effectiveness comparison (example)
| Group | Number of cases | Effective | Effectively | Effectively | Total effective rate (%) |
| Matched group | 14 | 6 | 4 | 3 | 92.86 |
| Treatment group | 14 | 4 | 4 | 3 | 78.57 |
After treatment group patient treatment, total effective rate is apparently higher than matched group, difference statistically significant (P < 0.05).
3.2 liang of group patient ECG's comparitive study
Result is in Table 2.
Table 2 matched group and treatment group patient ECG's comparitive study (example)
| Group | Number of cases | Effective | Effectively | Effectively | Total effective rate (%) |
| Matched group | 14 | 5 | 5 | 3 | 92.86 |
| Treatment group | 14 | 3 | 3 | 4 | 71.43 |
Treatment group patient ECG changes total effective rate apparently higher than matched group, difference statistically significant (P < 0.05).
3.3 liang of group untoward reaction situations compare
Matched group patient has 1 example pulsatile headache occur, disappears after adhering to taking medicine about 1 week, and obvious adverse reaction does not occur treatment group patient.
Result shows, medicine composite for curing coronary heart disease determined curative effect, after medicine composite for curing group patient treatment, total effective rate and ECG change total effective rate are obviously higher than matched group, difference all statistically significant (P < 0.05), all there is not obvious adverse reaction in two groups of patients.
Claims (8)
1. the pharmaceutical composition treating coronary heart disease, it is characterised in that composition and the weight portion of making the crude drug of this pharmaceutical composition be:
Earthworm fruit mustard 1800-1860 weight portion Herba Saniculae Astrantifoliae 1600-1680 weight portion asarinin 80-90 weight portion xylopinine 90-92 weight portion.
2. a kind of pharmaceutical composition treating coronary heart disease according to claim 1, it is characterised in that composition and the weight portion of making the crude drug of this pharmaceutical composition be:
Earthworm fruit mustard 1830 weight portion Herba Saniculae Astrantifoliae 1640 weight portion asarinin 85 weight portion xylopinine 91 weight portion.
3. a kind of pharmaceutical composition treating coronary heart disease according to claim 1, it is characterised in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to prepare into tablet or capsule or drop pill.
4. a kind of pharmaceutical composition treating coronary heart disease according to claim 1, it is characterised in that the treatment medicaments for coronary disease of pharmaceutical composition and chemical drugs or Chinese medicine composition.
5. the preparation method of the pharmaceutical composition treating coronary heart disease, it is characterised in that prepare as follows:
The composition of crude drug and weight portion be: earthworm fruit mustard 1800-1860 weight portion Herba Saniculae Astrantifoliae 1600-1680 weight portion asarinin 80-90 weight portion xylopinine 90-92 weight portion;
Preparation method:
(1) earthworm fruit mustard is taken by crude drug proportioning, Herba Saniculae Astrantifoliae, asarinin, xylopinine, mixing, with weight percent concentration 33% ethanol as solvent, extract at 45 DEG C of warm macerating, extraction time is 14 times, each extraction time is 3.0 hours, each solvent load is 28 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, it is concentrated into relative density 1.12, filter, medicinal liquid passes through D784 macroporous adsorptive resins, first wash with water, again with weight percent concentration 80% alcoholic solution eluting D784 macroporous adsorptive resins, collect weight percent concentration 80% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is taken, with weight percent concentration 70% ethanol as solvent, heating and refluxing extraction 2 times, each extraction time is 1.5 hours, each solvent load is 18 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, it is concentrated into relative density 1.15, filter, medicinal liquid passes through D185 macroporous adsorptive resins, first wash with water, again with weight percent concentration 90% alcoholic solution eluting D185 macroporous adsorptive resins, collect weight percent concentration 90% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) extract A and extract B are mixed, obtain pharmaceutical composition.
6. the preparation method of a kind of pharmaceutical composition treating coronary heart disease according to claim 5, it is characterised in that prepare as follows:
The composition of crude drug and weight portion be: earthworm fruit mustard 1830 weight portion Herba Saniculae Astrantifoliae 1640 weight portion asarinin 85 weight portion xylopinine 91 weight portion;
Preparation method:
(1) earthworm fruit mustard is taken by crude drug proportioning, Herba Saniculae Astrantifoliae, asarinin, xylopinine, mixing, with weight percent concentration 33% ethanol as solvent, extract at 45 DEG C of warm macerating, extraction time is 14 times, each extraction time is 3.0 hours, each solvent load is 28 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, it is concentrated into relative density 1.12, filter, medicinal liquid passes through D784 macroporous adsorptive resins, first wash with water, again with weight percent concentration 80% alcoholic solution eluting D784 macroporous adsorptive resins, collect weight percent concentration 80% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is taken, with weight percent concentration 70% ethanol as solvent, heating and refluxing extraction 2 times, each extraction time is 1.5 hours, each solvent load is 18 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, it is concentrated into relative density 1.15, filter, medicinal liquid passes through D185 macroporous adsorptive resins, first wash with water, again with weight percent concentration 90% alcoholic solution eluting D185 macroporous adsorptive resins, collect weight percent concentration 90% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) extract A and extract B are mixed, obtain pharmaceutical composition.
7. the preparation method of a kind of pharmaceutical composition treating coronary heart disease according to claim 5, it is characterised in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to prepare into tablet or capsule or drop pill.
8. the preparation method of a kind of pharmaceutical composition treating coronary heart disease according to claim 5, it is characterised in that pharmaceutical composition and chemical drugs or Chinese medicine composition treatment medicaments for coronary disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610047305.7A CN105641016A (en) | 2016-01-25 | 2016-01-25 | Pharmaceutical composition for treating coronary heart disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610047305.7A CN105641016A (en) | 2016-01-25 | 2016-01-25 | Pharmaceutical composition for treating coronary heart disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105641016A true CN105641016A (en) | 2016-06-08 |
Family
ID=56486812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610047305.7A Withdrawn CN105641016A (en) | 2016-01-25 | 2016-01-25 | Pharmaceutical composition for treating coronary heart disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105641016A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111808210A (en) * | 2020-09-01 | 2020-10-23 | 江西业力医疗器械有限公司 | Lumbrugua burclover polysaccharide, extraction method and application thereof |
-
2016
- 2016-01-25 CN CN201610047305.7A patent/CN105641016A/en not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111808210A (en) * | 2020-09-01 | 2020-10-23 | 江西业力医疗器械有限公司 | Lumbrugua burclover polysaccharide, extraction method and application thereof |
| CN111808210B (en) * | 2020-09-01 | 2021-01-19 | 西藏甘露藏药股份有限公司 | Lumbrugua burclover polysaccharide, extraction method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104225217B (en) | A kind of Chinese medicine preparation for treating coronary heart disease and preparation method thereof | |
| CN106668348A (en) | Pharmaceutical composition for treating diabetic retinopathy | |
| CN1304769A (en) | Blood-cleaning pill | |
| CN105395600A (en) | Application of cyclocarya paliurus extract in preparing medicine for treating cardiovascular and cerebrovascular diseases | |
| CN105641016A (en) | Pharmaceutical composition for treating coronary heart disease | |
| CN100486621C (en) | Chinese medicinal composition for treating hemilateral headache and its preparation method | |
| CN103830448A (en) | Medicament composition for treating coronary heart disease stenocardia and preparation method thereof | |
| CN111759891B (en) | Pharmaceutical composition for treating myocardial ischemia and application thereof | |
| CN106620056A (en) | Pharmaceutical composition for treating diabetic retinopathy | |
| CN106822206A (en) | It is a kind of to treat pharmaceutical composition of neurodermatitis and preparation method thereof | |
| CN106074736A (en) | A kind of pharmaceutical composition treating cerebral thrombosis and preparation method thereof | |
| CN106620045A (en) | Preparation method and application of 95% ethanol extract of clerodendrum japonicum roots | |
| CN106668546A (en) | Pharmaceutical composition for treating ceratitis | |
| CN106109927A (en) | A kind of pharmaceutical composition treating chloasma and preparation method thereof | |
| CN105287865A (en) | Medicinal composition for treating malignant tumor | |
| Wei et al. | Characteristics and Application Analysis of Traditional Chinese Medicine Containing Sophora Japonica | |
| CN104173808B (en) | A kind of Chinese medicine and preparation method thereof for treating flaming-up of the liverfire type hypertension | |
| CN106728476A (en) | Treat the pharmaceutical composition of diabetic retinopathy | |
| CN106727844A (en) | Treat the pharmaceutical composition of insomnia | |
| CN106852948A (en) | A kind of pharmaceutical composition for treating canker sore | |
| CN105535230A (en) | Medicine composition for treating coronary heart disease | |
| CN106511642A (en) | Pharmaceutical composition preventing diabetic retinopathy and preparation method for pharmaceutical composition | |
| CN104474158A (en) | Traditional Chinese medicine composition for treating coronary heart disease and application thereof | |
| CN106581326A (en) | Pharmaceutical composition for preventing and treating senile osteoporosis | |
| CN106581102A (en) | Pharmaceutical composition for treatment of uterine myoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160608 |
|
| WW01 | Invention patent application withdrawn after publication |